Rani Therapeutics’ pill platform accepted into FDA program

H.C. Wainwright reiterated a Buy rating and $11.00 price target for Rani Therapeutics (RANI) after its RaniPill platform was accepted into the FDA's Emerging Technology Program. The company reported Q2 EPS of $(0.04), beating estimates, and has $53.4M in cash. RANI also announced positive Phase 1 data for RT-114 and a partnership with PegBio for obesity treatments.

Rani Therapeutics (RANI) announced its RaniPill® Capsule™ platform was accepted into the FDA's Emerging Technology Program. This program supports innovative pharmaceutical technologies and provides early engagement with the FDA. The company aims to use this opportunity to advance its oral biologic delivery technology and automate manufacturing. Rani has partnerships with Chugai, ProGen, and PegBio for rare disease, immunology, and obesity treatments.

Rani Therapeutics Holdings, Inc. (RANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update ~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026~ ~ Announced positive initial Phase 1a da

Rani Therapeutics (Nasdaq: RANI) reported Q2 2026 results and updates on RT-114. In Phase 1a, oral RT-114 via the RaniPill Capsule showed bioavailability >150% vs matched subcutaneous PG-102, with similar half-life and no serious adverse events. Rani dosed an expansion cohort, plans Phase 1b repeat-dose obesity study by end-2026, and completed a $20m registered direct offering. Cash was $53.4m at June 30, 2026; Q2 contract revenue was $1.7m and net loss $8.4m.

Rani Therapeutics (RANI) reported Phase 1a results for RT-114, an oral RaniPill capsule delivering PG-102, a GLP-1/GLP-2 dual agonist from ProGen. In 30 healthy volunteers, oral RT-114 produced >150% systemic exposure vs 12 mg subcutaneous, with similar half-life (5.6 vs 5.3 days) and no serious adverse events. Phase 1b is underway; data expected in 2027.

The EU General Court upheld the European Commission's decision to block Booking Holdings' acquisition of eTraveli, citing concerns over entrenching Booking's dominance in the hotel OTA market. The ruling validates the EC's novel 'reverse leveraging' theory of harm, signaling heightened scrutiny of conglomerate mergers that expand ecosystems. Booking's appeal was rejected, and the judgment may impact future M&A strategies.